Literature DB >> 21877123

A note on the evaluation of BoNTA trial quality.

Vance W Berger, Diana Knoll.   

Abstract

In their systematic review, Zhang et al. evaluate randomized controlled trials on the efficacy of Botulinum toxin type A (BoNTA) in helping patients with musculoskeletal disorders. Scoring each trial according to the Jadad scale they note that the studies range from 1 to 5 with an average of 4.1, which they interpret as a testimony of the high quality of the studies included. Unfortunately, we cannot share the author's enthusiasm, as a perfect Jadad score of 5 is no guarantee that a study is of good quality.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21877123     DOI: 10.1007/s10787-011-0089-1

Source DB:  PubMed          Journal:  Inflammopharmacology        ISSN: 0925-4692            Impact factor:   4.473


  5 in total

Review 1.  The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis.

Authors:  Tony Zhang; Aleem Adatia; Wasifa Zarin; Misha Moitri; Abi Vijenthira; Rong Chu; Lehana Thabane; Walter Kean
Journal:  Inflammopharmacology       Date:  2010-11-13       Impact factor: 4.473

2.  Is the Jadad score the proper evaluation of trials?

Authors:  Vance W Berger
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

3.  Chewing gum and caries.

Authors:  Vance W Berger
Journal:  J Am Dent Assoc       Date:  2009-06       Impact factor: 3.634

4.  Treatment of lateral epicondylitis with botulinum toxin: a randomized, double-blind, placebo-controlled trial.

Authors:  Shiu Man Wong; Andrew C F Hui; Po-Yee Tong; Dawn W F Poon; Evelyn Yu; Lawrence K S Wong
Journal:  Ann Intern Med       Date:  2005-12-06       Impact factor: 25.391

Review 5.  A general framework for the evaluation of clinical trial quality.

Authors:  Vance W Berger; Sunny Y Alperson
Journal:  Rev Recent Clin Trials       Date:  2009-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.